

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM S-8

REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933

ICECURE MEDICAL LTD.

(Exact name of registrant as specified in its charter)

State of Israel

(State or other jurisdiction of  
incorporation or organization)

Not Applicable

(I.R.S. Employer  
Identification No.)

7 Ha'Eshel St., PO Box 3163  
Caesarea, 3079504 Israel  
(Address of Principal Executive Offices)

IceCure Medical Ltd. 2024 Employee Equity Incentive Plan  
(Full title of the plan)

Mr. Eyal Shamir  
Chief Executive Officer  
IceCure Medical Ltd.  
7 Ha'Eshel St., PO Box 3163  
Caesarea, 3079504 Israel  
Tel: +(972) 4 623 0333  
(Name, Address and Telephone Number of Agent For Service)

IceCure Medical Inc.  
10 W Prospect Street, Suite 401  
Nanuet, NY 10954  
Tel: +1 888 902 5716

Copies to:

Oded Har-Even, Esq.  
Eric Victorson, Esq.  
Sullivan & Worcester LLP  
1251 Avenue of the Americas  
New York, NY 10020  
Tel: (212) 660-3000

Adv. Reut Alfiah  
Adv. Gal Cohen  
Sullivan & Worcester Tel-Aviv (Har-Even & Co.)  
28 HaArba'a St. HaArba'a Towers  
North Tower, 35th floor  
Tel-Aviv, Israel 6473925  
Tel: +972 74-758-0480

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act

Large accelerated filer       Accelerated filer       Non-accelerated filer       Smaller reporting company       Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The documents containing the information required in Part I of this registration statement have been or will be sent or given to participating employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended, or the Securities Act, in accordance with the rules and regulations of the United States Securities and Exchange Commission, or the Commission. Such documents are not being filed with the Commission either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

In this registration statement, IceCure Medical Ltd. is sometimes referred to as "Registrant," the "Company," "we," "us" or "our."

### Item 3. Incorporation of Documents by Reference.

The following documents, which have been filed by the Company with the Commission are incorporated by reference in and made a part of this registration statement, as of their respective dates:

- (a) The Registrant's annual report for the fiscal year ended December 31, 2023 on [Form 20-F](#), filed with the Commission on April 3, 2024;
- (b) The Registrant's Reports of Foreign Private Issuer on Form 6-K submitted on [January 10, 2024](#); [January 12, 2024](#); [January 12, 2024](#); [January 30, 2024](#) (with respect to the first five paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [February 26, 2024](#) (with respect to the first through third paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [March 4, 2024](#) (with respect to the first five paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [March 12, 2024](#) (with respect to the first two paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [March 19, 2024](#) (with respect to the first two paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [April 2, 2024](#) (with respect to the first two paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [April 3, 2024](#); [April 15, 2024](#) (with respect to the first, second, third and fourth paragraphs, the first paragraph under the section titled "Topline Data Presented at the ASBrS 2024 Annual Meeting", the section titled "Healthcare Economics", and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [April 15, 2024](#); [May 7, 2024](#) (with respect to the first, second, third and sixth paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [May 21, 2024](#); [May 28, 2024](#) (excluding the second and third paragraphs in the press release attached as Exhibit 99.1 to the Form 6-K); [June 4, 2024](#) (with respect to the first, third and fourth paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [July 1, 2024](#) (with respect to the first and third paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [July 9, 2024](#) (with respect to the first and fourth paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [July 16, 2024](#); [July 22, 2024](#); [July 22, 2024](#) (with respect to the second, third and fourth paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); [August 6, 2024](#); [August 7, 2024](#) (with respect to the first three paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); and [August 14, 2024](#) (with respect to the first, second, fourth and fifth paragraphs and the section titled "Forward Looking Statements" in the press release attached as Exhibit 99.1 to the Form 6-K); and
- (c) The description of the Registrant's ordinary shares contained in the Registrant's registration statement on [Form 8-A](#) (File No. 001-40753), filed by the Registrant with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, on August 23, 2021, as amended by Exhibit 2.31 to our Annual Report on [Form 20-F](#) for the fiscal year ended December 31, 2023, filed with the SEC on April 3, 2024, including any further amendments or reports filed for the purpose of updating such description.

In addition to the foregoing, all documents subsequently filed by us with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

II-1

### Item 4. Description of Securities.

Not Applicable.

### Item 5. Interests of Named Experts and Counsel.

Not Applicable.

### Item 6. Indemnification of Directors and Officers.

The Companies Law 5759-1999, or the Companies Law, provide that a company may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:

- a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator's award approved by a court;
- reasonable litigation expenses, including attorneys' fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction;
- reasonable litigation expenses, including attorneys' fees, expended by the office holder or imposed on him or her by a court: (1) in proceedings that the company institutes, or that another person institutes on the company's behalf, against him or her; (2) in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and
- expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys' fees. An "Administrative Procedure" is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or II (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.

The Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount or criterion:

- to events that in the opinion of the board of directors can be foreseen based on the company's activities at the time that the undertaking to indemnify is made; and

- in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.

We have entered into indemnification agreements with all of our directors and with all members of our office holders. Each such indemnification agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not covered by directors and officer's insurance.

### Exculpation

Under the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included in its articles of association. Our articles of association provide that we may exculpate, in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty of care, but prohibit an exculpation from liability arising from a company's transaction in which our controlling shareholder or officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law.

II-2

### Limitations

The Companies Law provides that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.

Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.

Our articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law.

There are no service contracts between us or any of our subsidiaries, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits upon termination of service.

### Item 7. Exemption from Registration Claimed.

Not Applicable.

### Item 8. Exhibits.

- |       |  |
|-------|--|
| 3.1   | <a href="#">Articles of Association of the registrant (incorporated herein by reference to Exhibit 1.1 to our Registration Statement on Form F-1 (File No. 333-258660) filed with the SEC on August 9, 2021).</a>      |
| 5.1*  | <a href="#">Opinion of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.).</a>   |
| 23.1* | <a href="#">Consent of Brightman Almagor Zohar &amp; Co., A Firm in the Deloitte Global Network, Independent Registered Public Accounting Firm.</a>  |
| 23.2* | <a href="#">Consent of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.) (contained in Exhibit 5.1).</a>  |
| 24.1* | <a href="#">Power of Attorney (included on signature page).</a>  |
| 99.1  | <a href="#">IceCure Medical Ltd. 2024 Employee Equity Incentive Plan (incorporated herein by reference to Exhibit 4.9 to our Annual Report on Form 20-F (File No. 001-40753) filed with the SEC on April 3, 2024).</a> |
| 107*  | <a href="#">Filing Fee Table</a>   |

\* Filed herewith.

II-3

### Item 9. Undertakings.

(a) The Registrant hereby undertakes:

(1) To file, during any period in which offers, or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

II-4

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Caesarea, Israel, on August 16, 2024.

### ICECURE MEDICAL LTD.

By: /s/ Eyal Shamir  
Name: Eyal Shamir  
Title: Chief Executive Officer

## POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of IceCure Medical Ltd., hereby severally constitute and appoint Eyal Shamir and Ronen Tsimerman, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

<u>Person</u>	<u>Capacity</u>	<u>Date</u>
<u>/s/ Eyal Shamir</u> Eyal Shamir	Chief Executive Officer (Principal Executive Officer)	August 16, 2024
<u>/s/ Ronen Tsimerman</u> Ronen Tsimerman	Chief Financial Officer, Chief Operation Officer (Principal Financial and Accounting Officer)	August 16, 2024
<u>/s/ Ron Mayron</u> Ron Mayron	Chairman of the Board of Directors	August 16, 2024
<u>/s/ Doron Birger</u> Doron Birger	Director	August 16, 2024
<u>/s/ Yang Huang</u> Yang Huang	Director	August 16, 2024
<u>/s/ Oded Tamir</u> Oded Tamir	Director	August 16, 2024
<u>/s/ Sharon Levita</u> Sharon Levita	Director	August 16, 2024
<u>/s/ Vincent Chun Hung Chan</u> Vincent Chun Hung Chan	Director	August 16, 2024

II-5

**SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES**

Pursuant to the Securities Act of 1933, as amended, the undersigned, IceCure Medical Inc., the duly authorized representative in the United States of IceCure Medical Ltd., has signed this Registration Statement on Form S-8 on August 16, 2024.

/s/ Eyal Shamir

IceCure Medical Inc.



Sullivan & Worcester Tel Aviv  
28 HaArba'a St. HaArba'a Towers  
North Tower, 35th Floor  
Tel-Aviv, Israel

+972-747580480  
sullivanlaw.com

August 16, 2024

To: IceCure Medical Ltd.  
7 Ha'Eshel St., PO Box 3163  
Caesarea, 3079504 Israel

Re: **Registration Statement on Form S-8**

Ladies and Gentlemen:

We have acted as Israeli counsel for IceCure Medical Ltd., an Israeli Company (the "**Company**") in connection with the Registration Statement on Form S-8 (the "**Registration Statement**") filed by the Company on the date hereof with the U.S. Securities and Exchange Commission (the "**SEC**") under the Securities Act of 1933, as amended (the "**Securities Act**"). The Registration Statement relates to the registration of 3,500,000 of the Company's ordinary shares, no nominal value (the "**Shares**"), issuable under the IceCure Medical Ltd. 2024 Employee Equity Incentive Plan (the "**Plan**").

In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the Registration Statement to which this opinion is attached as an exhibit; (ii) a copy of the articles of association of the Company, as currently in effect; (iii) resolutions of the Board of Directors of the Company which relate to the Registration Statement and the Plan; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company. In addition, we have assumed that the Shares and any equity awards that provide for the acquisition thereof will be granted in accordance with the Plan and the Company's articles of association.

We are members of the Israel Bar and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of the State of Israel and have not, for the purpose of giving this opinion, made any investigation of the laws of any other jurisdiction than the State of Israel.

Based upon and subject to the foregoing, we are of the opinion that the Shares issuable under the Plan have been duly authorized and, when issued and paid for in accordance with the terms of the Plan and applicable option grant, will be validly issued, fully paid and non-assessable.

We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm wherever appearing in the Registration Statement in connection with Israeli law. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of the SEC's Regulation S-K under the Securities Act.

Very truly yours,

/s/ Sullivan & Worcester Tel Aviv (Har-Even & Co.)  
SULLIVAN & WORCESTER TEL AVIV (Har-Even & Co.)

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement on Form S-8 of IceCure Medical Ltd. (the "Company") of our report dated April 3, 2024, relating to the consolidated financial statements of the Company appearing in the Company's Annual Report on Form 20-F for the year ended December 31, 2023.

/s/ Brightman Almagor Zohar & Co.  
Brightman Almagor Zohar & Co.,  
Certified Public Accountants  
A firm in the Deloitte Global Network

Tel Aviv, Israel  
August 16, 2024

## Calculation of Filing Fee Tables

Form S-8  
(Form Type)

IceCure Medical Ltd.  
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation	Amount Registered <sup>(1)</sup>	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
<b>Newly Registered Securities</b>							
Fees to Be Paid	Equity	457(c)					
		457(h)	2,000,000 <sup>(2)</sup>	\$ 0.6 <sup>(4)</sup>	\$ 1,200,000	\$ 0.00014760	\$ 177.12
	Equity	457(c)	1,500,000 <sup>(3)</sup>	0.6 <sup>(4)</sup>	900,000	\$ 0.00014760	\$ 132.84
<b>Total Offering Amounts</b>					\$ 2,100,000		\$ 309.96
<b>Total Fees Previously Paid</b>							
<b>Total Fee Offsets</b>							
<b>Net Fee Due</b>							<u>\$ 309.96</u>

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement also covers an indeterminate number of additional securities which may be offered and issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions.
- (2) Represents Ordinary Shares reserved for issuance upon the exercise of options that may be granted under the IceCure Medical Ltd. 2024 Equity Incentive Plan, or the Plan, as amended from time to time.
- (3) Consists of ordinary shares issuable upon vesting and settlement of Restricted Shares and Restricted Shares Units (RSUs) that are outstanding under the Plan.
- (4) Estimated in accordance with Rule 457(c) and (h) under the Securities Act, based upon the average of the high and low sales prices of the Registrant's ordinary shares as reported on the Nasdaq Capital Market on August 9, 2024.